MicroRNAs As Diagnostic Biomarkers and Predictors of Antidepressant Response in Major Depressive Disorder: A Systematic Review

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2024 Apr 26

PMID 38665721

Authors

Beatriz A Carneiro

Livia N Franco Guerreiro-Costa

Daniel Lins-Silva

Daniela Faria Guimaraes

Lucca S Souza

Gustavo C Leal

Ana Teresa Caliman-Fontes

Graziele Beanes

Ryan Dos S Costa

Lucas C Quarantini

Affiliations

Soon will be listed here.

Abstract

Despite the hardships of major depressive disorder (MDD), biomarkers for the diagnosis and pharmacological management of this condition are lacking. MicroRNAs are epigenetic mechanisms that could provide promising MDD biomarkers. Our aim was to summarize the findings and provide validation for the selection and use of specific microRNAs as biomarkers in the diagnosis and treatment of MDD. A systematic review was conducted using the PubMed/Medline, Cochrane, PsycINFO, Embase, and LILACS databases from March 2022 to November 2023, with clusters of terms based on "microRNA" and "antidepressant". Studies involving human subjects, animal models, and cell cultures were included, whereas those that evaluated herbal medicines, non-pharmacological therapies, or epigenetic mechanisms other than miRNA were excluded. The review revealed differences in the expression of various microRNAs when considering the time of assessment (before or after antidepressant treatment) and the population studied. However, due to the heterogeneity of the microRNAs investigated, the limited size of the samples, and the wide variety of antidepressants used, few conclusions could be made. Despite the observed heterogeneity, the following microRNAs were determined to be important factors in MDD and the antidepressant response: mir-1202, mir-135, mir-124, and mir-16. The findings indicate the potential for the use of microRNAs as biomarkers for the diagnosis and treatment of MDD; however, more homogeneous studies are needed.

Citing Articles

A Cross-Sectional Trait Versus State Biomarker Analysis of Inflammatory Cytokines and miRNAs in Patients with Major Depressive Disorder.

Rockson C, Girish C, Natarajan H, Menon V Indian J Psychol Med. 2024; 47(1):57-64.

PMID: 39564330 PMC: 11572534. DOI: 10.1177/02537176241279110.

The researcher's guide to selecting biomarkers in mental health studies.

Verhoeven J, Wolkowitz O, Barr Satz I, Conklin Q, Lamers F, Lavebratt C Bioessays. 2024; 46(10):e2300246.

PMID: 39258367 PMC: 11811959. DOI: 10.1002/bies.202300246.

References

Belzeaux R, Lin C, Ding Y, Bergon A, Ibrahim E, Turecki G . Predisposition to treatment response in major depressive episode: A peripheral blood gene coexpression network analysis. J Psychiatr Res. 2016; 81:119-26. DOI: 10.1016/j.jpsychires.2016.07.009. View

Lo Iacono L, Ielpo D, Parisi C, Napoli G, Accoto A, Di Segni M . MicroRNA-34a regulates 5-HT2C expression in dorsal raphe and contributes to the anti-depressant-like effect of fluoxetine. Neuropharmacology. 2021; 190:108559. DOI: 10.1016/j.neuropharm.2021.108559. View

Pan B, Liu Y . Effects of duloxetine on microRNA expression profile in frontal lobe and hippocampus in a mouse model of depression. Int J Clin Exp Pathol. 2016; 8(11):15454-61. PMC: 4713700. View

Lopez J, Lim R, Cruceanu C, Crapper L, Fasano C, Labonte B . miR-1202 is a primate-specific and brain-enriched microRNA involved in major depression and antidepressant treatment. Nat Med. 2014; 20(7):764-8. PMC: 4087015. DOI: 10.1038/nm.3582. View

Cuschieri S . The STROBE guidelines. Saudi J Anaesth. 2019; 13(Suppl 1):S31-S34. PMC: 6398292. DOI: 10.4103/sja.SJA_543_18. View

Hooijmans C, Rovers M, De Vries R, Leenaars M, Ritskes-Hoitinga M, Langendam M . SYRCLE's risk of bias tool for animal studies. BMC Med Res Methodol. 2014; 14:43. PMC: 4230647. DOI: 10.1186/1471-2288-14-43. View

Zeng D, Shi Y, Li S, Xu F, Zhu W, Li H . miR-124 Exacerbates depressive-like behavior by targeting Ezh2 to induce autophagy. Behav Pharmacol. 2023; 34(2-3):131-140. DOI: 10.1097/FBP.0000000000000716. View

Lopez J, Kos A, Turecki G . Major depression and its treatment: microRNAs as peripheral biomarkers of diagnosis and treatment response. Curr Opin Psychiatry. 2017; 31(1):7-16. DOI: 10.1097/YCO.0000000000000379. View

Leistedt S, Linkowski P . Brain, networks, depression, and more. Eur Neuropsychopharmacol. 2012; 23(1):55-62. DOI: 10.1016/j.euroneuro.2012.10.011. View

10.

Liu W, Zhang F, Zheng Y, He S, Zhang T, Guo Q . The role of circulating blood microRNA-374 and microRNA-10 levels in the pathogenesis and therapeutic mechanisms of major depressive disorder. Neurosci Lett. 2021; 763:136184. DOI: 10.1016/j.neulet.2021.136184. View

11.

Garza-Manero S, Pichardo-Casas I, Arias C, Vaca L, Zepeda A . Selective distribution and dynamic modulation of miRNAs in the synapse and its possible role in Alzheimer's Disease. Brain Res. 2013; 1584:80-93. DOI: 10.1016/j.brainres.2013.12.009. View

12.

Gururajan A, Naughton M, Scott K, OConnor R, Moloney G, Clarke G . MicroRNAs as biomarkers for major depression: a role for let-7b and let-7c. Transl Psychiatry. 2016; 6(8):e862. PMC: 5022079. DOI: 10.1038/tp.2016.131. View

13.

Fiori L, Lopez J, Richard-Devantoy S, Berlim M, Chachamovich E, Jollant F . Investigation of miR-1202, miR-135a, and miR-16 in Major Depressive Disorder and Antidepressant Response. Int J Neuropsychopharmacol. 2017; 20(8):619-623. PMC: 5570004. DOI: 10.1093/ijnp/pyx034. View

14.

Dwivedi Y . Evidence demonstrating role of microRNAs in the etiopathology of major depression. J Chem Neuroanat. 2011; 42(2):142-56. PMC: 3163781. DOI: 10.1016/j.jchemneu.2011.04.002. View

15.

Oved K, Morag A, Pasmanik-Chor M, Oron-Karni V, Shomron N, Rehavi M . Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers. Pharmacogenomics. 2012; 13(10):1129-39. DOI: 10.2217/pgs.12.93. View

16.

Funatsuki T, Ogata H, Tahara H, Shimamoto A, Takekita Y, Koshikawa Y . Changes in Multiple microRNA Levels with Antidepressant Treatment Are Associated with Remission and Interact with Key Pathways: A Comprehensive microRNA Analysis. Int J Mol Sci. 2023; 24(15). PMC: 10418406. DOI: 10.3390/ijms241512199. View

17.

He S, Liu X, Jiang K, Peng D, Hong W, Fang Y . Alterations of microRNA-124 expression in peripheral blood mononuclear cells in pre- and post-treatment patients with major depressive disorder. J Psychiatr Res. 2016; 78:65-71. DOI: 10.1016/j.jpsychires.2016.03.015. View

18.

Belmaker R, Agam G . Major depressive disorder. N Engl J Med. 2008; 358(1):55-68. DOI: 10.1056/NEJMra073096. View

19.

Im H, Kenny P . MicroRNAs in neuronal function and dysfunction. Trends Neurosci. 2012; 35(5):325-34. PMC: 3565236. DOI: 10.1016/j.tins.2012.01.004. View

20.

Bocchio-Chiavetto L, Maffioletti E, Bettinsoli P, Giovannini C, Bignotti S, Tardito D . Blood microRNA changes in depressed patients during antidepressant treatment. Eur Neuropsychopharmacol. 2012; 23(7):602-11. DOI: 10.1016/j.euroneuro.2012.06.013. View